Loading clinical trials...
Loading clinical trials...
Long-Term Safety and Efficacy Follow-up of AB-1005 Gene Transfer Study Participants With Parkinson's Disease or Multiple System Atrophy
This is an observational, long term, follow-up study for participants with Parkinson's disease (PD) or Multiple System Atrophy-Parkinsonian subtype (MSA-P) who participated in prior interventional studies with AB-1005. It is intended to better understand the long-term safety of AB-1005, how well tolerated it is and how long lasting the effects are.
Age
All ages
Sex
ALL
Healthy Volunteers
No
University of California San Francisco
San Francisco, California, United States
Ohio State University
Columbus, Ohio, United States
Start Date
September 4, 2025
Primary Completion Date
September 30, 2037
Completion Date
March 30, 2038
Last Updated
October 2, 2025
132
ESTIMATED participants
Observation
OTHER
Lead Sponsor
AskBio Inc
NCT07310264
NCT02119611
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07216976